Nanomaterials for the treatment of spinal cord injury
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Graphene and Nanomaterials Applications · Nanoparticle-Based Drug Delivery · Nerve injury and regeneration
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Traumatic spinal injury: global epidemiology and worldwide volume10.1016/j.wneu.2018.02.033 ↗
2. Recent advances in nanomaterials for the treatment of spinal cord injury
3. The development of spinal cord anatomy10.1159/000121417 ↗
4. Combinatory repair strategy to promote axon regeneration and functional recovery after chronic spinal cord injury10.1038/s41598-017-09432-6 ↗
5. Required growth facilitators propel axon regeneration across complete spinal cord injury10.1038/s41586-018-0467-6 ↗
6. Microglia-organized scar-free spinal cord repair in neonatal mice10.1038/s41586-020-2795-6 ↗
7. Traumatic spinal cord injury-repair and regeneration10.1093/neuros/nyw080 ↗
8. Nanomedicine for treating spinal cord injury10.1039/c3nr00957b ↗
9. Bio-inspired dual-adhesive particles from microfluidic electrospray for bone regeneration10.1007/s12274-022-5202-9 ↗
10. Cell membrane-coated nanomaterials for cancer therapy
11. Current understanding of hydrogel for drug release and tissue engineering10.3390/gels8050301 ↗
12. Tailoring the component of protein corona via simple chemistry10.1038/s41467-019-12470-5 ↗
13. Glomerular barrier behaves as an atomically precise bandpass filter in a sub-nanometre regime10.1038/nnano.2017.170 ↗
14. Electrospun nanofibers for the delivery of active drugs through nasal, oral and vaginal mucosa: current status and future perspectives10.1016/j.msec.2020.110756 ↗
15. Strategies to enhance drug absorption via nasal and pulmonary routes10.3390/pharmaceutics11030113 ↗
16. Size-dependent translocation of nanoemulsions via oral delivery10.1021/acsami.7b04916 ↗
17. Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo10.1038/s41467-022-32281-5 ↗
18. Operation nasal vaccine-lightning speed to counter COVID-1910.1126/sciimmunol.add9947 ↗
19. Therapeutic targets and nanomaterial-based therapies for mitigation of secondary injury after spinal cord injury10.2217/nnm-2021-0113 ↗
20. Current state of knowledge on intelligent-response biological and other macromolecular hydrogels in biomedical engineering: a review10.1016/j.ijbiomac.2022.12.148 ↗
21. Nanozyme-based remodeling of disease microenvironments for disease prevention and treatment: a review10.1021/acsanm.3c02097 ↗
22. Epidemiology of traumatic spinal cord injury in Tianjin, China: an 18-year retrospective study of 735 cases10.1080/10790268.2017.1415418 ↗
23. Is graphene shortening the path toward spinal cord regeneration?10.1021/acsnano.2c04756 ↗
24. Modulation of neural activity for myelination in the central nervous system10.3389/fnins.2019.00952 ↗
25. The acute respiratory management of cervical spinal cord injury in the first 6 weeks after injury: a systematic review10.1038/sc.2010.39 ↗
26. Traumatic spinal cord injury10.1038/nrdp.2017.18 ↗
27. Perioperative medicine: managing for outcome10.1097/ALN.0000000000004209 ↗
28. Spinal cord injury: an overview
29. Recent advances in nanoplatforms for the treatment of neuropathic pain10.1038/s41393-021-00746-x ↗
30. Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury10.1016/j.jconrel.2015.08.060 ↗
31. Acute and non-resolving inflammation associate with oxidative injury after human spinal cord injury10.1093/brain/awaa360 ↗
32. Clinical translation of stem cell based interventions for spinal cord injury - are we there yet?10.1016/j.addr.2017.09.021 ↗
33. Nontraumatic spinal cord injury: incidence, epidemiology, and functional outcome10.1016/S0003-9993(99)90162-4 ↗
34. Pulmonary inhalation for disease treatment: basic research and clinical translations
35. Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application10.1186/s12951-024-02298-7 ↗
36. Functional biomaterials for osteoarthritis treatment: from research to application10.1002/SMMD.20220014 ↗
37. Pathophysiology and pharmacologic treatment of acute spinal cord injury10.1016/j.spinee.2003.07.007 ↗
38. The pathology of human spinal cord injury: defining the problems10.1089/089771504323004575 ↗
39. Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade10.55782/ane-2011-1848 ↗
40. Time-dependent changes in the microenvironment of injured spinal cord affects the therapeutic potential of neural stem cell transplantation for spinal cord injury10.1186/1756-6606-6-3 ↗
41. Macrophage activation and its role in repair and pathology after spinal cord injury10.1016/j.brainres.2014.12.045 ↗
42. Dealing with danger in the CNS: the response of the immune system to injury10.1016/j.neuron.2015.05.019 ↗
43. Modern medical management of spinal cord injury10.1007/s11910-019-0984-1 ↗
44. Steroids for acute spinal cord injury
45. Carrier-free deferoxamine nanoparticles against iron overload in brain10.31635/ccschem.022.202101696 ↗
46. HAp thermosensitive nanohydrogel cavities act as brood pouches to incubate and control-release NSCs for rapid spinal cord injury therapy10.1002/adfm.202203492 ↗
47. Highly permeable DNA supramolecular hydrogel promotes neurogenesis and functional recovery after completely transected spinal cord injury10.1002/adma.202102428 ↗
48. A reactive oxygen species-responsive hydrogel encapsulated with bone marrow derived stem cells promotes repair and regeneration of spinal cord injury
49. Nanovector-mediated drug delivery for spinal cord injury treatment10.1002/wnan.1276 ↗
50. Nanofiber scaffolds for treatment of spinal cord injury10.2174/0929867321666140815124648 ↗
51. Spinal cord injury10.1080/09638280110110640 ↗
52. Risks from accidental exposures to engineered nanoparticles and neurological health effects: a critical review10.1186/1743-8977-7-42 ↗
53. Recent advances in benefits and hazards of engineered nanoparticles10.1016/j.etap.2012.07.011 ↗
54. Safety of nanoparticles in medicine10.2174/1389450115666140804124808 ↗
55. Ice-inspired lubricated drug delivery particles from microfluidic electrospray for osteoarthritis treatment10.1021/acsnano.1c09325 ↗
56. Biomass microcapsules with stem cell encapsulation for bone repair
57. Therapy of spinal cord injury by zinc pyrogallol modified nanozyme via anti-inflammatory strategies10.1016/j.cej.2023.144595 ↗
58. Rutin, a natural flavonoid protects PC12 cells against sodium nitroprusside-induced neurotoxicity through activating PI3K/Akt/mTOR and ERK1/2 pathway10.1007/s11064-015-1690-2 ↗
59. Carrier-free nanodrug based on co-assembly of methylprednisolone dimer and rutin for combined treatment of spinal cord injury10.1021/acsnano.3c00360 ↗
60. Mesoporous polydopamine delivering 8-gingerol for the target and synergistic treatment to the spinal cord injury10.1186/s12951-023-01896-1 ↗
61. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
62. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications10.1016/j.jconrel.2014.12.030 ↗
63. Advanced engineered nanoparticulate platforms to address key biological barriers for delivering chemotherapeutic agents to target sites10.1016/j.addr.2020.06.030 ↗
64. High drug-loaded microspheres enabled by controlled in-droplet precipitation promote functional recovery after spinal cord injury10.1038/s41467-022-28787-7 ↗
65. Blood–spinal cord barrier in spinal cord injury: a review10.1089/neu.2020.7413 ↗
66. Recent advances in nanotherapeutic strategies for spinal cord injury repair10.1016/j.addr.2018.12.011 ↗
67. Nanocarrier-mediated inhibition of macrophage migration inhibitory factor attenuates secondary injury after spinal cord injury10.1021/nn505980z ↗
68. Advanced approaches for improving bioavailability and controlled release of anthocyanins10.1016/j.jconrel.2021.11.031 ↗
69. A dual-targeted multifunctional nanoformulation for potential prevention and therapy of alzheimer's disease
70. Cellular- and subcellular-targeted delivery using a simple all-in-one polymeric nanoassembly10.1002/anie.202008272 ↗
71. Perfluorocarbon@porphyrin nanoparticles for tumor hypoxia relief to enhance photodynamic therapy against liver metastasis of colon cancer10.1021/acsnano.0c05617 ↗
72. Pure drug nano-assemblies: a facile carrier-free nanoplatform for efficient cancer therapy10.1016/j.apsb.2021.08.012 ↗
73. Carrier-free nanodrugs for safe and effective cancer treatment10.1016/j.jconrel.2020.10.014 ↗
74. Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: from intrinsic physicochemical properties to external modification
75. Synthetic porous melanin10.1021/jacs.0c10465 ↗
76. Mesoporous polydopamine carrying manganese carbonyl responds to tumor microenvironment for multimodal imaging-guided cancer therapy
77. Rapid and efficient removal of Cr(vi) by a core–shell magnetic mesoporous polydopamine nanocomposite: roles of the mesoporous structure and redox-active functional groups10.1039/D1TA02475B ↗
78. Mesoporous polydopamine carrying sorafenib and SPIO nanoparticles for MRI-guided ferroptosis cancer therapy10.1016/j.jconrel.2020.01.048 ↗
79. Polydopamine-based simple and versatile surface modification of polymeric nano drug carriers10.1021/nn405809c ↗
80. Cancer preventive properties of ginger: a brief review10.1016/j.fct.2006.11.002 ↗
81. 8-gingerol ameliorates myocardial fibrosis by attenuating reactive oxygen species, apoptosis, and autophagy via the PI3K/Akt/mTOR signaling pathway10.3389/fphar.2021.711701 ↗
82. Berberine-loaded MSC-derived sEVs encapsulated in injectable GelMA hydrogel for spinal cord injury repair10.1016/j.ijpharm.2023.123283 ↗
83. Extracellular vesicles versus synthetic nanoparticles for drug delivery10.1038/s41578-020-00277-6 ↗
84. A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury10.1089/neu.2009.1149 ↗
85. Fabrication of active targeting lipid nanoparticles: challenges and perspectives
86. Siegwart, Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs10.1038/s41578-022-00529-7 ↗
87. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates10.1126/sciadv.add4623 ↗
88. Surface functionalization of nanoparticles for nanomedicine10.1039/c2cs15294k ↗
89. Effective repair of traumatically injured spinal cord by nanoscale block copolymer micelles10.1038/nnano.2009.303 ↗
90. Scar tissue-targeting polymer micelle for spinal cord injury treatment
91. Targeted drug delivery to macrophages10.1517/17425247.2013.751370 ↗
92. Role of microglia in neurotrauma10.1016/j.nurt.2010.07.002 ↗
93. Repertoire of microglial and macrophage responses after spinal cord injury10.1038/nrn3053 ↗
94. Selective nanovector mediated treatment of activated proinflammatory microglia/macrophages in spinal cord injury10.1021/nn4036014 ↗
95. Controlled delivery of a neurotransmitter-agonist conjugate for functional recovery after severe spinal cord injury10.1038/s41565-023-01416-0 ↗
96. Nanoparticle biointerfacing by platelet membrane cloaking10.1038/nature15373 ↗
97. Novel optimized drug delivery systems for enhancing spinal cord injury repair in rats10.1080/10717544.2021.2009937 ↗
98. Nano-carrier mediated co-delivery of methyl prednisolone and minocycline for improved post-traumatic spinal cord injury conditions in rats10.1080/03639045.2017.1291669 ↗
99. Tan · J. Colloid. Interface. Sci. · 2024 · 662 · 85710.1016/j.jcis.2024.02.085 ↗
100. Construction and performance evaluation of pH-responsive oxidized hyaluronic acid hollow mesoporous silica nanoparticles10.1016/j.ijbiomac.2023.128656 ↗